JPWO2021154812A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021154812A5
JPWO2021154812A5 JP2022545141A JP2022545141A JPWO2021154812A5 JP WO2021154812 A5 JPWO2021154812 A5 JP WO2021154812A5 JP 2022545141 A JP2022545141 A JP 2022545141A JP 2022545141 A JP2022545141 A JP 2022545141A JP WO2021154812 A5 JPWO2021154812 A5 JP WO2021154812A5
Authority
JP
Japan
Prior art keywords
glycoprotein
cov
immunogenic composition
adjuvant
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022545141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512648A5 (https=
JP7792339B2 (ja
JP2023512648A (ja
Publication date
Priority claimed from US16/997,001 external-priority patent/US10953089B1/en
Application filed filed Critical
Priority claimed from PCT/US2021/015220 external-priority patent/WO2021154812A1/en
Publication of JP2023512648A publication Critical patent/JP2023512648A/ja
Publication of JP2023512648A5 publication Critical patent/JP2023512648A5/ja
Publication of JPWO2021154812A5 publication Critical patent/JPWO2021154812A5/ja
Priority to JP2025184688A priority Critical patent/JP2026026092A/ja
Application granted granted Critical
Publication of JP7792339B2 publication Critical patent/JP7792339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022545141A 2020-01-27 2021-01-27 コロナウイルスワクチン製剤 Active JP7792339B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025184688A JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202062966271P 2020-01-27 2020-01-27
US62/966,271 2020-01-27
US202062976858P 2020-02-14 2020-02-14
US62/976,858 2020-02-14
US202062983180P 2020-02-28 2020-02-28
US62/983,180 2020-02-28
US202063048945P 2020-07-07 2020-07-07
US63/048,945 2020-07-07
US202063051706P 2020-07-14 2020-07-14
US63/051,706 2020-07-14
US202063054182P 2020-07-20 2020-07-20
US63/054,182 2020-07-20
US16/997,001 2020-08-19
US16/997,001 US10953089B1 (en) 2020-01-27 2020-08-19 Coronavirus vaccine formulations
US202063129392P 2020-12-22 2020-12-22
US63/129,392 2020-12-22
PCT/US2021/015220 WO2021154812A1 (en) 2020-01-27 2021-01-27 Coronavirus vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025184688A Division JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Publications (4)

Publication Number Publication Date
JP2023512648A JP2023512648A (ja) 2023-03-28
JP2023512648A5 JP2023512648A5 (https=) 2024-02-02
JPWO2021154812A5 true JPWO2021154812A5 (https=) 2024-02-02
JP7792339B2 JP7792339B2 (ja) 2025-12-25

Family

ID=77079351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022545141A Active JP7792339B2 (ja) 2020-01-27 2021-01-27 コロナウイルスワクチン製剤
JP2025184688A Pending JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025184688A Pending JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Country Status (14)

Country Link
US (1) US20230070886A1 (https=)
EP (1) EP4097123A4 (https=)
JP (2) JP7792339B2 (https=)
KR (1) KR20220141302A (https=)
CN (1) CN115720581A (https=)
AU (1) AU2021214064A1 (https=)
BR (1) BR112022014830A2 (https=)
CA (1) CA3165371A1 (https=)
GB (1) GB2610070A (https=)
IL (1) IL295142A (https=)
MX (1) MX2022009167A (https=)
TW (1) TW202142555A (https=)
WO (1) WO2021154812A1 (https=)
ZA (1) ZA202401922B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
WO2022235663A1 (en) * 2021-05-05 2022-11-10 Novavax, Inc. Coronavirus and influenza compositions and methods for using them
CN113773372B (zh) * 2021-08-15 2024-08-02 北京科兴中维生物技术有限公司 重组蛋白及其制备方法和应用
CN116041448B (zh) * 2021-08-26 2025-05-13 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
EP4436984A1 (en) * 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Coronavirus immunogen compositions and their uses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20240125935A (ko) * 2021-11-30 2024-08-20 노바백스, 인코포레이티드 코로나바이러스 백신 제형물
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
EP4709741A1 (en) * 2023-05-12 2026-03-18 Icosavax, Inc. Coronavirus spike glycoprotein receptor binding domains and uses thereof
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1508615A1 (en) * 2003-08-18 2005-02-23 Amsterdam Institute of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
US20070124833A1 (en) * 2005-05-10 2007-05-31 Abad Mark S Genes and uses for plant improvement
JP5813513B2 (ja) * 2008-12-09 2015-11-17 ノババックス，インコーポレイテッド 修飾ｒｓｖｆタンパク質及びその使用方法
US20130122032A1 (en) * 2011-09-30 2013-05-16 Gale Smith Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
KR102399854B1 (ko) * 2013-09-19 2022-05-19 노바백스, 인코포레이티드 면역원성 중동호흡기증후군 코로나바이러스 (ΜＥＲＳ-ＣｏＶ) 조성물 및 방법
EP4494650A3 (en) * 2015-09-03 2025-03-26 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
US20170354729A1 (en) * 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
EP4599847A3 (en) * 2016-10-25 2025-11-12 Trustees of Dartmouth College Prefusion coronavirus spike proteins and their use
MA47790A (fr) * 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
CN111499692B (zh) * 2020-06-16 2020-12-04 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用

Similar Documents

Publication Publication Date Title
JP2026026092A5 (https=)
JPWO2021154812A5 (https=)
CA1320163C (en) Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
CN1122530C (zh) 疫苗
JP5683811B2 (ja) キメラインフルエンザウイルス様粒子
TWI640534B (zh) 抗ｒｓｖ疫苗
TW202142555A (zh) 冠狀病毒疫苗配製品
MXPA02003067A (es) Uso de combinacion de ester sorbitano de polioxietileno y octoxinol como adjuvante y su uso en vacunas.
CZ2002843A3 (cs) Vakcinační prostředek
RU2018111760A (ru) Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью
WO2020063370A2 (zh) 免疫组合物及其制备方法与应用
CN106659777A (zh) 免疫原性组合产品
KR101361769B1 (ko) Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신
US20240252612A1 (en) Immunogenic compositions and uses thereof
WO2019191623A1 (en) Respiratory syncytial virus (rsv) vaccines
BRPI0811692A2 (pt) material com imunogenicidade
JP2002512003A (ja) パラミキソウイルスワクチンのためのアルファウイルスベクター
JP2021518152A5 (https=)
US20220275346A1 (en) Hantavirus antigenic composition
JPWO2022203963A5 (https=)
JPWO2002062381A1 (ja) バキュロウイルスベクターワクチン
US20240261392A1 (en) Compositions and methods to increase coronavirus immune response
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
JP4705591B2 (ja) 抗原または免疫原に対する免疫応答を仕立てる方法。
WO1998046263A1 (en) Saponin adjuvants in combination with dna vaccination